Japan’s PMDA Adds ‘Safety Net’ Initiative To Resolve Drug Lag: An Interview With PMDA (part 2 of 2)
This article was originally published in The Pink Sheet Daily
In part 2 of this series, Kaoru Misawa outlines PMDA’s intentions for the initiative and industry reaction in Japan.
You may also be interested in...
Japan Launches ‘Safety Net’ Initiative As PMDA Looks To Resolve Drug Lag With The West (Part 1 of 2)
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has started a new pilot program for risk management, tentatively being called the "product management" initiative. Under the initiative, a group will be created within PMDA's Office of Safety to oversee a new drug throughout its life cycle. Initial plans called for only a handful of drugs being involved. The agency hopes to finish the pilot program within six months, in time for the initiative to be operational some time in the spring
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.
New rules separate medical devices from pharma regulations to provide clarity and regulatory efficiency, removing approval hurdles for devices and software in 2014.